These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 15108167)

  • 21. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
    Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
    Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cathepsin D and prognosis in breast cancer.
    Tandon AK; Clark GM; Chamness GC; Chirgwin JM; McGuire WL
    N Engl J Med; 1990 Feb; 322(5):297-302. PubMed ID: 2296271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy.
    Dinshaw KA; Budrukkar AN; Chinoy RF; Sarin R; Badwe R; Hawaldar R; Shrivastava SK
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1132-41. PubMed ID: 15978744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
    Scorilas A; Diamandis EP; Levesque MA; Papanastasiou-Diamandi A; Khosravi MJ; Giai M; Ponzone R; Roagna R; Sismondi P; López-Otin C
    Clin Cancer Res; 1999 Jul; 5(7):1778-85. PubMed ID: 10430082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
    Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
    Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
    Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients.
    Alo' PL; Visca P; Marci A; Mangoni A; Botti C; Di Tondo U
    Cancer; 1996 Feb; 77(3):474-82. PubMed ID: 8630954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S; Gutierrez J; Avisar E
    Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in breast cancer.
    Merkel DE; Osborne CK
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):641-52. PubMed ID: 2558104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survivin expression predicts early recurrence in early-stage breast cancer.
    Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
    Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
    Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The prognostic significance of cathepsin D in primary breast cancer].
    Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Schaeffer HJ; Stützer H; Bolte A
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):545-51. PubMed ID: 8001750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [What are the prognostic factors in operable breast cancer without histologic axillary lymph node invasiveness. Results of an uni- and multifactorial analysis].
    Chevallier B; Heintzman F; Mosseri V; Graic Y; Bastit P; Dauce JP; Maisse P; Cauchois D; Cabanne JP; Asselain B
    Bull Cancer; 1989; 76(1):51-60. PubMed ID: 2713515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
    Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
    Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.